Last mentioned: Mar 8, 2026
Earnings Previews
Seeking Alpha releases Q4 2025 previews for both Voyager and Zevra.
CFO Appointment
Zevra Therapeutics names Justin Renz as Chief Financial Officer.
Voyager Partnership Update
Voyager reports progress on TRACER platform milestones with Novartis.
Miplyffa Approval
Zevra receives FDA approval for arimoclomol in NPC.
Voyager Technologies and Zevra Therapeutics are set to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution and platform validation. Investors are focused on Zevra's Miplyffa launch trajectory and Voyager's CNS-focused partnership revenue.
This page surfaces every story mentioning Voyager Technologies, Inc. across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Voyager Technologies, Inc. was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |